EDSA Stock Summary and Trading Ideas (Edesa Biotech - Common Shares | NASDAQ:EDSA)

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Edesa Biotech - Common Shares trades on the NASDAQ stock market under the symbol EDSA.

As of October 30, 2026, EDSA stock price declined to $2.57 with 30,335 million shares trading.

EDSA has a beta of -0.92, meaning it tends to be less sensitive to market movements. EDSA has a correlation of 0.00 to the broad based SPY ETF.

EDSA has a market cap of $24.78 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, EDSA traded as high as $20.32 and as low as $.72.

The top ETF exchange traded funds that EDSA belongs to (by Net Assets): VXF.

EDSA has outperformed the market in the last year with a price return of +37.4% while the SPY ETF gained +12.3%. However, in the short term, EDSA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -51.0% vs +2.1% return in SPY. But in the last 2 weeks, EDSA shares have fared better than the market returning 0.0% compared to SPY -1.0%.

EDSA support price is $2.49 and resistance is $2.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EDSA shares will trade within this expected range on the day.